Centrient Pharmaceuticals Receives Gold Sustainability Rating from EcoVadis

Centrient Pharmaceuticals is proud to announce it has once again received a Gold Sustainability rating from EcoVadis. This affirms Centrient Pharmaceuticals’ commitment to environmental, social, and ethical sustainability and underlines our position as a sustainable leader in the generics pharmaceuticals space.

The Gold Sustainability rating ranks Centrient Pharmaceuticals among the top 4% of companies assessed by EcoVadis in the manufacturing of basic pharmaceutical products and pharmaceutical preparations under the themes of Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. This year, Centrient Pharmaceuticals received Advanced standing in all four categories.

“We are very proud that Centrient has received a Gold rating from EcoVadis,” states our Chief Executive Officer, Rex Clements. “This demonstrates our continued commitment, for the fourth year in a row, in producing foundational medicines sustainably and reliably.”

Centrient Pharmaceuticals’ products help millions of people fight life-threatening illnesses and live healthier lives. In 2022, over 1.5 billion patient treatments were facilitated by Centrient worldwide. We work hard towards our purpose of enhancing the well-being of patients across the globe through our core focus on sustainability, which influences our daily decisions and is integral to our strategic vision.

EcoVadis is the world’s most trusted provider of business sustainability ratings, providing detailed assessments of business’ environmental, social, and ethical performance. Based on leading standards, such as GRI, UNGC, and ISO 26000, the rating is supervised by an international scientific committee. EcoVadis ratings have been tested on over 100,000+ companies across 200+ industries and 175+ countries.